MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
Zynex Net Debt 2011-2026 | ZYXI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.8 M | -40.4 M | -17.5 M | -29.1 M | -39.2 M | -9.36 M | -10.1 M | -5.21 M | 2.78 M | 4.32 M | 4.77 M | 5.74 M | 5.34 M | 2.89 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.74 M | -40.4 M | -11.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
15.2 M | $ 32.5 | -8.14 % | $ 1.44 B |  USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 13.77 | 4.86 % | $ 1.97 B | USA |
 |
Bio-Rad Laboratories
BIO
|
754 M | $ 269.87 | 0.53 % | $ 7.61 B | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.53 | -1.12 % | $ 122 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
-16.5 M | $ 14.58 | -1.22 % | $ 394 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 6.36 | 0.32 % | $ 457 M |  Israel |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 39.87 | 0.77 % | $ 5.94 K | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 75.27 | 1.21 % | $ 111 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.52 | - | $ 169 M |  France |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 23.17 | -5.16 % | $ 196 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 46.0 | 1.39 % | $ 1.43 B | USA |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
Delcath Systems
DCTH
|
-2.46 M | $ 9.94 | 2.0 % | $ 283 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
InMode Ltd.
INMD
|
-34.8 M | $ 14.0 | -1.41 % | $ 905 M | Israel |
 |
Establishment Labs Holdings
ESTA
|
131 M | $ 78.78 | 5.1 % | $ 2.22 B |  Costa-rica |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 99.04 | -2.22 % | $ 1.25 B | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.55 | -0.22 % | $ 122 M | USA |
 |
Globus Medical
GMED
|
-511 M | $ 92.25 | -1.25 % | $ 12.5 B | USA |
 |
LivaNova PLC
LIVN
|
130 M | $ 69.26 | 1.32 % | $ 3.76 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
-36.1 M | $ 1.51 | 2.03 % | $ 59.1 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.88 | - | $ 1.14 M | USA |
 |
Medtronic PLC
MDT
|
23.6 B | $ 97.06 | -1.57 % | $ 125 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 11.57 | -1.66 % | $ 891 M | USA |
 |
MiMedx Group
MDXG
|
-85.3 M | $ 5.35 | 0.28 % | $ 786 M | USA |